Solomon Moshkevich - 27 Feb 2026 Form 4 Insider Report for Natera, Inc. (NTRA)

Role
PRESIDENT, CLINICALDIAGNOSTICS
Signature
/s/ Tami Chen, Attorney-in-Fact
Issuer symbol
NTRA
Transactions as of
27 Feb 2026
Net transactions value
-$550,396
Form type
4
Filing time
03 Mar 2026, 21:05:04 UTC
Previous filing
04 Feb 2026
Next filing
11 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN /s/ Tami Chen, Attorney-in-Fact 03 Mar 2026 0002010019

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTRA Common Stock Award +10,051 +7.3% 147,898 27 Feb 2026 Direct F1, F2
transaction NTRA Common Stock Options Exercise $49,149 +5,125 +3.5% $9.59 153,023 02 Mar 2026 Direct
transaction NTRA Common Stock Sale $185,114 -931 -0.61% $198.83 152,092 02 Mar 2026 Direct F3, F4
transaction NTRA Common Stock Sale $318,971 -1,594 -1% $200.11 150,498 02 Mar 2026 Direct F3, F5
transaction NTRA Common Stock Sale $95,460 -475 -0.32% $200.97 150,023 02 Mar 2026 Direct F3, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTRA Stock Option (right to buy) Options Exercise $0 -5,125 -100% $0.000000 0 02 Mar 2026 Common Stock 5,125 $9.59 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on March 1, 2027 and the remaining RSUs vest in 12 equal quarterly installments thereafter.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.42 to $199.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.6750 to $200.5100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.72 to $201.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The option shares are fully exercisable.